{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:44:57Z","timestamp":1793724297313,"version":"4.6.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates (ADCs) exhibit structurally driven and highly heterogeneous toxicities, yet most pharmacovigilance studies remain drug-centered and lack systematic component-level evaluation. This study provides a comprehensive real-world safety assessment of FDA-approved ADCs using a component-based analytical framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All adverse event (AE) reports for 14 FDA-approved ADCs (2004\u20132024) were extracted from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). ADCs and AEs were included when positive signals were simultaneously detected by four disproportionality methods (reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayes geometric mean (EBGM)) under a multi-method consensus criterion (MCC). AEs were classified using MedDRA at the preferred term (PT) and system organ class (SOC) levels. Signal prioritization was performed by ranking ROR values within each key component type\u2014antibody subtype, linker type, payload category, and drug-to-antibody ratio (DAR) value class, with the top 20 signals designated as \u201cstrong signals.\u201d False discovery rate (FDR) correction was applied for sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52,699 positive PT-level AE signals were included across 13 ADCs. Distinct toxicity signatures were observed across component types: IgG1-based ADCs demonstrated prominent ocular and corneal toxicity and treatment-related secondary lymphoma, whereas IgG4-based ADCs were dominated by hepatobiliary injury, vascular toxicity, bone marrow suppression, and severe infections. ADCs with cleavable linkers showed toxicity patterns enriched for treatment-related secondary lymphoma, pulmonary toxicity, and infections, while non-cleavable linker ADCs showed a highly distinctive pattern dominated by ocular toxicity, particularly corneal epithelial and stromal injury. DNA-damaging payload ADCs exhibited severe systemic toxicities, including hepatobiliary toxicity, vascular injury, interstitial lung disease, serious infections, and bone marrow suppression. In contrast, microtubule inhibitor payloads mainly produced ocular and corneal toxicity, treatment-related secondary lymphoma, and local hemorrhagic events. DAR 3\u20135 ADCs were highly enriched for ocular toxicity and treatment-related secondary lymphoma; DAR &amp;lt; 3 ADCs were characterized by hepatobiliary injury and infection-dominant patterns, and DAR &amp;gt; 5 ADCs demonstrated a heterogeneous multi-organ toxicity profile spanning metabolic, hepatic, pulmonary, infectious, neurological, vascular, and ocular domains. All MCC-identified PT-level AE signals remained significant after FDR correction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large-scale real-world evaluation reveals clear component type-specific toxicity signatures among ADCs, supporting more targeted safety monitoring and informing rational ADC design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1702195","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:38:19Z","timestamp":1770964699000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A real-world study of adverse event profiles associated with the four key components of antibody\u2013drug conjugates based on the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuning","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, the Fifth Affiliated Hospital, Wenzhou Medical University","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fifth Affiliated Hospital, Wenzhou Medical University","place":["Lishui, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fifth Affiliated Hospital, Wenzhou Medical University","place":["Lishui, Zhejiang, China"]},{"name":"School of Pharmacy, Hangzhou Medical College","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-world outcomes of relapsed\/refractory diffuse large B-cell lymphoma treated with polatuzumab vedotin-based therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"Hemasphere"},{"key":"B3","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","article-title":"Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions","volume":"24","author":"Chen","year":"2025","journal-title":"Mol. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/abt\/tbaf004","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103853","DOI":"10.1016\/j.breast.2024.103853","article-title":"Safety profile of sacituzumab govitecan in patients with breast cancer: a systematic review and meta-analysis","volume":"79","author":"Dacoregio","year":"2025","journal-title":"Breast"},{"key":"B9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jmb.2013.10.039","article-title":"Structural determinants of unique properties of human IgG4-Fc","volume":"426","author":"Davies","year":"2014","journal-title":"J. Mol. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1097\/JS9.0000000000002435","article-title":"Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database","volume":"111","author":"Duan","year":"2025","journal-title":"Int. J. Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/cancers15153886","article-title":"Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence","volume":"15","author":"Gogia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B13","volume-title":"Guideline on good pharmacovigilance practices (GVP) module IX: signal management (Rev 1)","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00432-021-03732-1","article-title":"Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"148","author":"Kloehn","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/14712598.2020.1802423","article-title":"Antibody-drug conjugates to treat gastric cancer","volume":"21","author":"Koganemaru","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2387317","article-title":"Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system","volume":"18","author":"Lin","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/jop.2022.0006","article-title":"Characterization and potential mitigation of corneal effects in nonclinical toxicology studies in animals administered depatuxizumab mafodotin","volume":"38","author":"Loberg","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.6004\/jadpro.2023.14.4.4","article-title":"Management of ocular toxicity in patients receiving belantamab mafodotin","volume":"14","author":"Lu","year":"2023","journal-title":"J. Adv. Pract. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","article-title":"Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report","volume":"14","author":"Marquant","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/cancers15112948","article-title":"Belantamab mafodotin: from clinical trials data to real-life experiences","volume":"15","author":"Mor\u00e8","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"1","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102574","DOI":"10.1016\/j.canep.2024.102574","article-title":"Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer","volume":"90","author":"Reike","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00198-023-06877-6","article-title":"A real-world pharmacovigilance study of abaloparatide based on the FDA adverse event reporting system (FAERS)","volume":"34","author":"Shi","year":"2023","journal-title":"Osteoporos. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/14740338.2023.2277801","article-title":"A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system","volume":"23","author":"Sun","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40360-025-00965-5","article-title":"Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FEARS)","volume":"26","author":"Sun","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jjco\/hyae054","article-title":"Antibody-drug conjugates in solid tumors; new strategy for cancer therapy","volume":"54","author":"Takakura","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","article-title":"Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis","volume":"44","author":"Tang","year":"","journal-title":"Cancer Metastasis Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1362484","DOI":"10.3389\/fphar.2024.1362484","article-title":"A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)","volume":"15","author":"Tang","year":"","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10147-024-02481-8","article-title":"Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study","volume":"29","author":"Taoka","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3390\/cancers12103041","article-title":"Fc-Engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies","volume":"12","author":"van der Horst","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","article-title":"Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma","volume":"11","author":"Wahab","year":"2021","journal-title":"Front. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/psp4.12738","article-title":"Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab-arm exchange with endogenous IgG4 in healthy volunteers","volume":"11","author":"Wang","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"105573","DOI":"10.1016\/j.esmoop.2025.105573","article-title":"Toxicity and efficacy of antibody-drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials","volume":"10","author":"Woodford","year":"2025","journal-title":"ESMO Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/0008-5472","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1702195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:28:34Z","timestamp":1771928914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1702195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":44,"alternative-id":["10.3389\/fphar.2026.1702195"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1702195","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1702195"}}